Outcomes of 5-aminosalicylates withdrawal due to non-adherence in ulcerative colitis patients: A step toward evaluating intermittent therapy
Rattachement africain : tr. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: 5-aminosalicylates (5-ASA) are the primary treatment for mild to moderate ulcerative colitis (UC). Maintenance therapy with 5-ASA has been shown to reduce both the risk of relapse and colorectal cancer. AIM: To evaluate the outcomes of 5-ASA withdrawal due to non-adherence in UC patients while in remission on monotherapy. METHODS: Adult patients with UC who were followed up between July 2019 and April 2025 were screened. Patients in remission receiving 5-ASA monotherapy who experienced treatment withdrawal due to non-adherence were included in this study. RESULTS: Among 880 patients with UC, 30 (3.4%) had 5-ASA withdrawal due to non-adherence while in remission on monotherapy. Twelve patients (40%) had disease relapse after a median of 20 months. The rate of patients in remission was 89% in the first year, decreasing to 73% in the second year, and to 64% in the third year. There were no significant differences between patients with and without relapse in terms of demographics, disease extent, remission duration before 5-ASA withdrawal, previous medications, steroid dependence, 5-ASA formulation, baseline inflammatory markers, or partial and endoscopic Mayo scores. Most patients (75%) who experienced relapse were successfully treated with 5-ASA monotherapy, while one-fourth of them required corticosteroids. No patients required biologic agents, hospitalization, or surgical intervention. CONCLUSION: Intermittent therapy may be safe and feasible for UC patients, especially those in long-term remission, with treatment interruption up to one year considered acceptable.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Outcomes of 5-aminosalicylates withdrawal due to non-adherence in ulcerative colitis patients: A step toward evaluating intermittent therapy
- Date Crossref
- 14/08/2025
- Éditeur
- Baishideng Publishing Group Inc.
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Bilkent University pays non établi dans la noticeUniversité ou école supérieure
-
Memorial Ankara Hospital pays non établi dans la noticeÉtablissement de santé
-
Ankara Numune Eğitim ve Araştırma Hastanesi pays non établi dans la noticeÉtablissement de santé
-
Başkent University Hospital pays non établi dans la noticeÉtablissement de santé
-
Ankara Yıldırım Beyazıt University pays non établi dans la noticeUniversité ou école supérieure
-
Hacettepe University pays non établi dans la noticeUniversité ou école supérieure
-
Ankara Bilkent City Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Ankara Yildirim Beyazit University Yenimahalle Training and Research Hospital Department of Gastroenterology pays non établi dans la noticeUniversité ou école supérieure
-
Faculty of Medicine Department of Gastroenterology pays non établi dans la noticeUniversité ou école supérieure
Bilkent University, Memorial Ankara Hospital et Ankara Numune Eğitim ve Araştırma Hastanesi, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.